transient receptor potential cation channel subfamily C member 5Genealiases: PPP1R159 · TRP5
Q-omics provides the consensus-scored TRPC5 profile across patient tissues and cancer cell-line models. TRPC5 expression is associated with patient survival in 22 of 34 cancer types, with the highest sampling consensus in THCA. Among the 18 cancer types available for tumor–normal comparison, TRPC5 is differentially expressed in 8, with the highest sampling consensus in THCA. Additionally, TRPC5 RNA expression shows 14,879 significant gene co-expression associations, with the highest sampling consensus in TGCT. Together, these results highlight THCA, and TGCT as cancer lineages where TRPC5 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for TRPC5 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes TRPC5 survival associations across molecular data types. TRPC5 RNA expression shows survival associations in the most cancer types (22), followed by mutation status (12) and mass-spec protein abundance (1). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible TRPC5 RNA expression–survival associations across cancer types. High TRPC5 expression shows unfavorable associations in ACC, LUAD, CHOL and KICH, but favorable associations in THCA and ESCA. The THCA Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify THCA as the clearest survival context for TRPC5 RNA expression.
This table summarizes TRPC5 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 8, while mass-spec protein shows differences in 3. The strongest signals are observed in THCA for RNA and LUAD for protein.
This table ranks reproducible tumor–normal expression differences for TRPC5. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. TRPC5 shows lower tumor expression in KIRC, KICH, CHOL and LIHC and higher tumor expression in THCA and HNSC. The THCA box plot shows higher TRPC5 RNA expression in tumor versus normal tissue (log2 FC = +1.829, t-test p < 0.001).
This table shows molecular features associated with TRPC5 in patient tissues and cancer cell lines. In patient samples, TRPC5 shows the broadest associations at the RNA and protein expression levels, with TGCT recurring as the lineage with the largest associated feature set. In cancer cell lines, TRPC5 RNA and mutation anchors are most strongly linked to RNA-expression features, especially in OVARY, while CRISPR and shRNA rows add functional-dependency signals in SKIN and LARGE_INTESTINE.
